Key takeaways
- US: an FDA advisory committee backed six peptides in July, and HHS issued an enforcement-discretion policy for the same six in October.
- US: FDA’s August warning letters treated “research use only” peptide products as unapproved new drugs; states moved both ways (Mississippi restricted, Louisiana protected compounding).
- Australia: the TGA issued a public notice, seized products, reported infringement notices over alleged melanotan II supply, and stated that supplying unapproved peptides is unlawful.
- UK: the MHRA said retatrutide sales are illegal and seized fake retatrutide and tirzepatide pens.
- Sport: WADA’s 2027 List, in force from 1 January 2027, adds examples to S0.
01November 2026
Newest first. Each entry has a date, the jurisdiction, one line, and a link to the primary document: a regulator page, the Federal Register, legislation or an official meeting record. Jurisdictions: US, UK, AU (Australia), INT (international sport).
We found no regulator action on peptides in our three markets between 1 and 17 November. The two-week comment window opened by the Federal Register notice of 30 October has closed.
02October 2026
| Date | Where | What happened | Primary source |
|---|---|---|---|
| 30 Oct | US | HHS peptide policy published in the Federal Register. The Federal Register publishes notice of HHS’s “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (91 FR 68526, Docket HHS-OASH-2026-0496), with a two-week comment window. | Federal Register 2026-22192 |
| 28 Oct | US | HHS files enforcement-discretion policy for six peptides. HHS says it does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, epitalon, KPV, MOTS-c, Semax or TB-500 under ten conditions until a final rule; interim, non-binding and not an approval. | HHS policy and appendices |
| 14 Oct | UK | MHRA seizes fake retatrutide and tirzepatide pens. MHRA and West Midlands Police seize more than 12,000 fake retatrutide and tirzepatide pens in Birmingham (announced 15 Oct); the MHRA repeats that retatrutide is not authorised in the UK. | MHRA press release |
03September 2026
| Date | Where | What happened | Primary source |
|---|---|---|---|
| 21 Sep | INT | WADA publishes the 2027 Prohibited List. Approved on 10 Sep and in force from 1 Jan 2027, the 2027 List adds further examples to S0 (non-approved substances) and leaves GLP-1 receptor agonists off the List. | WADA release |
| 1 Sep | US | PEPTIDES for Veterans Act introduced. H.R. 10212 is introduced in the House and referred to the Committee on Veterans’ Affairs; it would direct the VA to review peptide regulations and study peptide-based therapies; it is a bill, not law. | Bill text, govinfo |
04August 2026
| Date | Where | What happened | Primary source |
|---|---|---|---|
| 24 Aug | US | FDA warning letters to online peptide sellers. FDA letters dated 24 Aug (posted 1 Sep) treat peptide products labelled “research use only” as unapproved new drugs because website evidence showed human use, and cite bacteriostatic water sold for reconstitution. | FDA letter 735127 |
| 19 Aug | US | Mississippi boards: no research-grade peptides in practice. Mississippi’s boards of medical licensure, nursing and pharmacy jointly state that healthcare providers may not compound, administer or dispense non-FDA-approved or research-grade peptides. | Joint statement |
| 17 Aug | AU | TGA announces seizure allegedly linked to an influencer. With NSW Police (warrants executed 4 Aug), the TGA seizes more than $120,000 of peptide and steroid products allegedly linked to a social media influencer and states that importing, advertising, manufacturing and supplying unapproved peptides is unlawful. | TGA media release |
| 17 Aug | AU | TGA safety advisory on melanotan II. TGA testing finds inconsistent amounts of melanotan II in seized nasal sprays; the advisory reports 27 infringement notices, totalling $101,412 and paid in May 2026, issued to a NSW individual for alleged unlawful supply. | TGA safety advisory |
| 1 Aug | US | Louisiana Act 374 takes effect. Licensing boards may not stop a Louisiana pharmacist compounding and dispensing peptides in compliance with section 503A and applicable USP chapters. | Board of Pharmacy bulletin |
05July 2026
| Date | Where | What happened | Primary source |
|---|---|---|---|
| 24 Jul | US | FDA advisory committee votes, day 2. The Pharmacy Compounding Advisory Committee backs epitalon and Semax for the 503A bulks list (outcome recorded in HHS’s October policy) and, by press report, rejects emideltide (DSIP); FDA staff had proposed rejecting all three, and FDA has not yet posted minutes. | HHS policy, Appendix B |
| 24 Jul | UK | MHRA warns that retatrutide sales are illegal. The MHRA says retatrutide “has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally.” | MHRA press release |
| 23 Jul | US | FDA advisory committee votes, day 1. The committee backs BPC-157, KPV, TB-500 and MOTS-c for the 503A bulks list against FDA staff proposals; reported votes 8–6–1 for the first three and 7–5–2 for MOTS-c (press-reported). | HHS policy, Appendix B |
| 20 Jul | AU | TGA puts peptide promoters and suppliers on notice. The TGA warns promoters, importers and suppliers of unapproved peptides of compliance action and says manufacture includes “applying a label to a blank vial”. | TGA media release |
Vote counts are press-reported until FDA posts minutes; see the 2026 PCAC vote.
06What this log leaves out
This log lists regulatory actions only. Industry news (telehealth launches, company lawsuits), scientific papers and platform moderation are left out. So are items we could not date at a primary source. Earlier 2026 events are covered on the market pages: US, UK and Australia, with the overview at are peptides legal?
This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.